Addiction Toxicology Case Conference - August 2021
-
Register
- Non-member - Tier I - Free!
- Non-member - Tier II - Free!
- Non-member - Tier III - Free!
- Non-member - Tier IV - Free!
- Member - Tier I - Free!
- Member - Tier II - Free!
- Member - Tier III - Free!
- Member - Tier IV - Free!
Already registered?
Log in now.
Case 1
Xylazine in the illicit drug supply and a cluster of overdose deaths.
Case 2
Vaccine hesitancy in substance use disorder treatment.
Series Moderators
- Timothy J. Wiegand, MD, FACMT, DFASAM (ACMT/ASAM Expert), Director of Toxicology and of the Toxicology Consult Service, University of Rochester Medical Center, Rochester, NY
- Gloria J. Baciewicz, MD (ASAM Expert), Medical Director, Strong Recovery; Professor of Clinical Psychiatry, Department of Psychiatry, University of Rochester Medical Center, Rochester, NY
Panelists
- Joseph D’Orazio, MD, FAAEM, FACMT (ACMT Expert) Associate Professor of Clinical Emergency Medicine; Director, Division of Medical Toxicology, Department of Emergency Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA
- Jeanmarie Perrone, MD, FACMT (ACMT Expert) Professor, Department of Emergency Medicine; Director, Division of Medical Toxicology and Addiction Medicine Initiatives, Perelman School of Medicine; Director, Penn Center for Addiction Medicine and Policy, University of Pennsylvania, Philadelphia, PA
- Kelly S. Ramsey, MD, MPH, MA, FACP, FASAM (ASAM Expert) Chief of Medical Services, New York State Office of Addiction Services and Supports, Albany, NY
- Mayra Rodriguez Beltran, PA-C (Guest Expert) Director of Medical Services, Huther Doyle, Rochester, NY
- Edwin A. Salsitz, MD, DFASAM (ASAM Expert) Associate Clinical Professor of Psychiatry, Icahn School of Medicine, Mount Sinai Beth Israel, New York, NY
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is open to the public.